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Chapter I: Introduction

In a cohort study of 224 maintenance hemodialysis (MHD) patients, Noori, et al. found
that both a higher dietary intake of phosphorus (P) and a ratio of higher P to protein (pro)
intake were associated with increased mortality risk in hemodialysis (HD) patients.(1)
Furthermore, dietary P restriction to control serum P is usually tied to a reduction in pro
intake, which is associated with muscle wasting and poor survival.(2) One highly prevalent
complication of end stage renal disease is protein energy wasting (PEW), a state of
decreased body protein stores and fat mass, which is strongly associated with increased
morbidity and mortality in the hemodialysis (HD) population.(3) The purpose of this study
was to analyze the extent to which diet composition is associated with PEW parameters
(serum chemistry, body mass, muscle mass, and dietary intakes).
It was hypothesized that the patients whose diets contained the lowest P/pro ratio would
demonstrate the fewest clinical indicators of PEW. Results from this and future studies
may help in designing diets to minimize PEW in the HD population.
As part of an initial screening phase for a collaborate multi-centered interventional clinical
trial involving HD patients from both Michigan (United States) and Selangor (Malaysia),
data was collected from several HD clinics in Klang Valley, an area in Malaysia centered
in Kuala Lumpur. The diverse ethnic population is this area, comprised of Indian, Malay,
and Chinese patients, differs vastly from the predominately African American patient pool
found in Michigan. To the best of our knowledge, this is the first study to assess the
relationship between the ratio of P/pro intakes and measures of PEW in a group of
Malaysian MHD patients.
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CHAPTER II: REVIEW OF LITERATURE
Chronic kidney disease and end-stage renal disease
According to the United States Renal Data System (USRDS), a surveillance system that
collects, analyzes, and reports information about chronic kidney disease and end-stage
renal disease (ESRD) in the United States, there were 661,648 prevalent cases of ESRD
in the U.S. in 2013, an increase of 68% since 2000.

(4)

The Malaysian Society of

Nephrology also maintains a registry of dialysis patients, reporting annually on ESRD
trends. Malaysia has experienced a similar rise in the number of prevalent dialysis patients,
with a 63% increase from 2005 to 2014. (5) Long-term survival on dialysis remains poor,
with a 54% survival rate after five years of ESRD onset in Malaysia and after three years
in the United States.

(6; 7)

Cardiovascular disease (CVD) comorbidity, reported at ten to

thirty times higher in CKD patients as compared to the general population, partially
explains increased mortality rates observed with CKD.

In Malaysia, CVD related

comorbidity accounted for 37% of all deaths for ESRD patients in 2014.

(7)

This

interrelationship of CKD and CVD metabolic derangements is referred to as cardiorenal
(CRS) syndrome. The underlying pathophysiologies in CRS include a myriad of hormonal,
hemodynamic, and CKD related factors, such as inflammation, calcium-phosphate
imbalance, and anemia.(8)

In both the United States and Malaysia, diabetes is the principal cause of CKD, followed
by hypertension. Types of renal replacement therapy (RRT) that replace the non-endocrine
functions of the kidney include dialysis (both hemodialysis and peritoneal) hemofiltration,
and hemodialfiltration. While a kidney transplant, regarded as the gold standard in RRT,
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does restore regulatory hormones, abnormalities of bone and mineral metabolism persist
in most patients. (9)

Protein Energy Wasting
The term protein energy wasting (PEW), characterized by a loss of body pro mass and fuel
reserves, was proposed by the International Society of Renal Nutrition and Metabolism
(ISRNM) in 2007. Etiologies of PEW include multiple factors that affect nutrient
metabolism, as outlined in Table 1.
Table 1
Causes of PEW
Decreased Nutrient Intake
Anorexia
Dietary Restrictions
Depression
Obstacles to food
purchases/preparation
Decreased physical activity
Endocrine/Hormonal Dysfunction
Insulin Resistance
Decreased insulin-like growth
factor-1
Vitamin D deficiency
Hyperparathyroidism
Increased pro catabolism
Decreased anabolism
Inflammation
Oxidative and carbonyl stress
Metabolic acidosis
Volume overload
Comorbidities
Diabetes
CVD
Congestive heart failure
Nutrient losses during dialysis
(3)
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The pathophysiology of PEW is complex and involves overlapping mechanisms as
depicted in Figure 1

(3; 10; 11)

Estimated prevalence of PEW ranges from twenty to fifty

percent, with higher rates observed during the later stages of CKD due to activation of proinflammatory cytokines, hypercatabolic states and declines in nutrient intakes.(12)
Figure 1
Schematic representation of the causes and manifestations of the pro–energy
wasting syndrome in kidney disease

Reprinted from reference (11)

PEW has been associated with higher morbidity and mortality and poorer quality of life
(QOL) in ESRD patients.

(13)

Four clinical indicators proposed by the ISRNM for the

diagnosis of PEW in CKD are outlined in Table 2. PEW is evident if criteria for at least
three of the four categories [serum chemistry, body mass index (BMI), muscle mass, and
dietary intake] are met.(3)
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Table 2
Criteria for the clinical diagnosis of pro-energy wasting in chronic kidney disease
Serum Chemistry
Serum albumin <3.8 g/dla
Serum prealbumin (transthyretin) <30 mg/dl (for
maintenance dialysis patients only)a
Serum cholesterol <100 mg/dla
BMI
BMI (edema-free) <23b
Unintentional weight loss over time: 5% over 3 months
or 10% over 6 months
Total body fat percentage <10%
Muscle Mass
Reduced muscle mass 5% over 3 months or 10% over 6
months
Reduced mid-arm muscle circumference areac (reduction
>10% in relation to 50th percentile of reference
population) Creatinine appearanced
Dietary Intake
Unintentional low dietary pro intake <0.80 g/kg/day for
at least 2 months for dialysis patients or <0.6g/kg/day for
patients with CKD stages G2–5
Unintentional low dietary energy intake <25 kcal/kg/day
for at least 2 months
a

Not valid if low concentrations are due to abnormally great urinary or gastrointestinal pro losses, liver
disease, or cholesterol-lowering medicines
b
A lower BMI might be desirable for certain Asian populations; weight must be edema-free mass, for
example, post-dialysis dry weight.
c
Measurement must be performed by a trained anthropometrist
d
Creatinine appearance is influenced by both muscle mass and meat intake
d
Can be assessed by dietary diaries and interviews, or for pro intake by calculation of normalized pro
equivalent of total nitrogen appearance (nPNA or nPCR) as determined by urea kinetic measurements.(11)

PEW Criteria
1. Serum chemistry
Albumin
Hypoalbuminemia is a strong predictor of both cardiovascular and all-cause mortality in
all stages of CKD. In the Nutritional and Inflammatory Evaluation in Dialysis Study, an
observational analysis of over 3000 maintenance HD patients, both a low normalized
protein nitrogen appearance (nPNA), a surrogate for dietary pro intake, and an
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inflammatory state were associated with low serum albumin.(14; 15) It was noted that nPNA,
a measurement of net pro degradation calculated using several dialysis parameters, might
overestimate dietary pro intake due to catabolism of endogenous nitrogen in states of
inflammation. (16) Albumin, a negative acute phase reactant, has been criticized as a reliable
marker of malnutrition. Albumin is a water-soluble negatively charged pro synthesized in
the liver. Functions include maintaining oncotic pressure, modulating coagulation by
preventing platelet aggregation, binding free radicals and bacterial toxins and heavy metals,
and transporting molecules such as fatty acids, thyroid hormones, steroids, bilirubin,
calcium, and magnesium in plasma. (17) Serum levels of albumin fall due to fluid overload,
infection, and inflammation, which trigger mechanisms leading to increased degradation
and reduced production. Many dialysis clinics use albumin level as a qualitative rationale
for supplement use, placing unsupported importance on this marker as an indicator of
malnutrition. Albumin may preferably be utilized as a marker underlying illness and
inflammation.(18; 19; 20)

Serum Cholesterol
Hypercholesterolemia in the general population is a known cardiovascular risk factor;
however, within the HD population an inverse association of total cholesterol with
mortality is observed. Dyslipidemia in CKD, which may be indicated by elevated plasma
cholesterol, hypertriglyceridemia, high lipoprotein(a) [Lp(a)], low high-density lipoprotein
cholesterol (HDL-C) or dysfunctional HDL particles is highly prevalent in ESRD patients.
Elevated low-density lipoprotein cholesterol (LDL-C), and thus total cholesterol, is not a
distinct characteristic of uremic dyslipidemia. Reduction in LDL-C in patients not taking
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lipid-lowering medication may be the result of inflammation and malnutrition.
Furthermore, although serum LDL-C may not be elevated, this lipoprotein is often
modified by oxidation and carbamylation with an increase in the proportion of small dense
LDL (sdLDL) subtype. (21; 22; 23)

2. Body Mass Index (BMI)
Whereas normal weight BMI within a healthy population is associated with a lower allcause mortality risk, a higher BMI improves survival in both CHD, heart failure and
dialysis patients.(24; 25) This phenomenon is known as the “obesity paradox” or “reverse
epidemiology.”

(15; 26)

However, this survival advantage for cardiovascular mortality

within the HD population is lost in the presence of inflammation, as indicated by both CRP
and albumin levels.(27) It is speculated that a higher lean body mass, not fat mass, is
responsible for the protective effects observed within the higher BMI groups.(25)

3. Muscle Mass
Anthropometric measures of skeletal muscle mass are an indirect assessment of muscle
protein. Since about sixty percent of total body protein is located in skeletal muscle, muscle
wasting may indicate a loss of muscle protein in response to poor nutritional intake.
Anthropometric measurements used to estimate muscle mass include triceps skinfold
thickness (TSF), an estimation of body fat, mid-upper arm circumference (MAC), and
mid-arm muscle area (MAMA) or mid-arm muscle circumference (MAMC), a formula
which indirectly estimates muscle mass (see Table 3). TSF is a measurement taken using
calipers at the mid-line on the posterior surface of the arm over the triceps muscle. MAMC
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is a calculated measurement derived from deducting TSF from mid-upper arm
circumference. An arm muscle area equation that corrects for bone area can provide a more
accurate assessment of bone-free muscle area; however, the corrected equation is neither
validated for elderly patients, nor appropriate for use in obese individuals.

(28)

Using the

non-fistula arm, three measurements of TSF and MAC are typically taken after dialysis,
and either the average or highest value is used for comparison to standard percentiles of a
reference population (e.g. NHANES I). Efforts have been made to develop standardized
MAMC tables specific to the hemodialysis population. A higher MAMC, an indicator of
lean body mass, and higher TSF, an indicator of fat mass, have each been associated with
a decrease in mortality in hemodialysis patients. (29; 30)
Table 3 (31)
Mid arm fat area (AFA)

AFA (cm2) =

𝑀𝐴𝐶 (𝑐𝑚)𝑥 𝑇𝑆𝐹(𝑐𝑚)

𝜋𝑥

Mid arm muscle circumference area (MAMA)

(𝑇𝑆𝐹)2

2

–

4
[𝑀𝐴𝐶 (𝑐𝑚)−(𝜋 𝑥 𝑇𝑆𝐹)]2

MAMA (cm2) =
4𝜋
Mid-arm muscle Circumference (MAMC)
MAMC (cm) = MAC (cm) –
[𝜋 𝑥 𝑇𝑆𝐹 (𝑐𝑚)]
Body frame size is determined by a person's wrist circumference in relation to his height
(https://www.nlm.nih.gov/medlineplus/ency/imagepages/17182.htm)

Values less than the 5th percentile for both arm muscle area and arm fat area indicate severe depletion. Values
between the 5th and 10th percentiles for both arm muscle area and arm fat area represent moderate depletion

Several studies have demonstrated successful use of a dynamometer to measure handgrip
strength as an indirect assessment of muscle mass in the HD population. A recent study of
330 HD patients found that both muscle strength and muscle mass were strong predictors
of mortality, with HGS demonstrating a stronger association with mortality when
compared to muscle mass.

(32)

With similar results found in measurements of HGS taken

both before and after HD sessions, this functional test is emerging as a reliable indicator of
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muscle mass, although current research is still lacking sufficient data to establish
parameters to define muscle wasting.

(33; 34; 35)

Body composition measurements, such as bioimpedance analysis (BIA), are frequently
used to evaluate fluid balance in the HD population. These devices can also measure
several nutritional related markers, such as lean and fat tissue mass

(23)

. Given the HD

population is prone to fluid shifts between intra and extracellular spaces, anthropometric
and body composition devices that cannot distinguish between different body
compartments of tissue, fat mass and fluid may inaccurately estimate LBM.

(36; 37)

BIA

estimates total body water (TBW) and lean and fat tissue masses by measuring resistance
(or impedance) to the flow of an electrical current passed through the body. Hydration
status, blood pressure, age and gender can alter the bioelectrical impedance, providing
misleading results.(38) Recently, ultrasound techniques that account for fluid shifts are
emerging as a useful tool for estimating LBM.(39)

4. Dietary Intake
Unintentional inadequate pro and energy intake is causally linked to PEW. Declines in
appetite occur in the early stages of CKD and may be exacerbated by multiple causes such
as uremic metabolites and imposed dietary restrictions. (2; 12) As CKD progresses, appetite
and intake continue to decline as the dialysis treatment itself can result in physiological
and metabolic effects which impact appetite and missed meals during treatment.(40)

Nutritional Assessment Tools
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As part of the nutrition care process, assessment of the HD patient includes both a medical
history (nutrition intake, biochemical data, medical tests and procedures, anamnesis) and a
physical examination (anthropometric measurements, signs of fat and muscle wasting) to
determine diagnosis, intervention, monitoring and evaluation. (41; 42) A 2012 survey of 599
Registered Dietitians, 91% of whom worked in the US, revealed that collection of dietary
intake is not a standard clinical practice due to time and resource constraints. 70% of
dietitians collect intake data only if abnormal laboratory results are found. Two-thirds of
dietitians reported analyzing nutrient intake based on estimations without software use.(43)
Blood chemistry, such as albumin, serum P, potassium, Kt/V (a measurement of treatment
adequacy where K = dialyzer clearance of urea, t = dialysis time, and V = volume of
distribution of urea, approximately equal to patient's total body water), lipoproteins,
electrolytes, glucose, and nPCR (normalized pro catabolic rate), also known as normalized
pro nitrogen appearance (nPNA) provide valuable information of physiological imbalances
and nutritional deficiencies. (44) Use of nPNA, which measures net protein degradation, is
considered a valid reflection of dietary protein intake (DPI) in steady state conditions. PNA
may overestimate DPI during periods of inflammation, be inaccurate for obese,
malnourished and edematous patients, and typically underestimates dietary pro intake by
approximately 6–8 g of pro per day. (14; 16)
Nutrition focused physical examinations, conducted to detect nutritional deficiencies and
complete anthropometric and body composition measurements, though gaining popularity
in clinical practice, are still used primarily in research. Several screening tools and scoring
systems, such as the subjective global assessment (SGA) and the Geriatric Nutritional Risk
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Index (GNRI), and are available to evaluate and monitor changes to nutritional status of
the HD patient.(45)

Phosphorus Homeostasis
Phosphorus, the second most abundant mineral in the body, is found in every cell. In an
adult, about 85% is complexed with calcium as hydroxyapatite in the bone and 15% is
distributed in the intracellular space throughout fluids and soft tissues, with less than 1%
found in the plasma.

P is not only a structural component of phospholipids (the major

component of cell membranes), nucleotides and nucleic acids, but is also involved in
several metabolic processes (e.g. is a buffering agent in maintaining pH, stored chemical
energy in the form of adenosine tri-phosphate (ATP), and cell signaling through
phosphorylation and dephosphorylation).(46)

Physiological process of regulating net phosphate balance
Intestinal Absorption of Phosphate
Ingested P is absorbed both passively and actively through the duodenum, jejunum and
ileum of the gastrointestinal tract (GIT) (47). The primary route of P absorption in the GIT
is via passive paracellular diffusion, linearly associated with luminal phosphate
concentration, so that a higher dietary intake of P results in increased total amount of
absorption.

P is also actively transported via sodium-phosphate 2b (NaPi-2b) co-
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transporters across the enterocyte. (48; 49) Additionally, calcitriol, or 1,25(OH)2D, stimulates
intestinal phosphate absorption by enhancing expression of NaPi-2b co-transporters. (50)

Phosphorus Distribution in the body
Following absorption, inorganic phosphate in the extracellular fluid moves freely in and
out of the skeleton, along with calcium, as a consequence of bone remodeling. This critical
inorganic phosphate component in the extracellular space makes up less than 0.1 percent
of total body P at a concentration of approximately 1 mmol/liter (3.1 mg/dl).(46; 49)

Renal Reabsorption of Phosphorus
In a healthy kidney, approximately 75% of filtered P is reabsorbed by the glomerulus in
the proximal tubule across the hormonally regulated type 2 sodium phosphate cotransporters, NaPi-2a and NaPi-2c.

(51; 52)

The distal tubule, loop of Henle and collecting

duct reclaim the remaining P. The kidneys excrete excess P in the amount of approximately
700-900 mg per day.(49) With diminished functioning of the nephrons in CKD, the kidney
lose their ability to excrete excess phosphorus, resulting in hyperphosphatemia.

Hormonal Regulatory Mechanisms of Serum Phosphorus
In order to understand the underlying pathways involved in P homeostasis and the difficulty
in managing hyperphosphatemia in CKD, a brief review of the hormonal mechanisms of P
homeostasis is provided. As depicted in Figure 2, the interplay between fibroblast growth
factor-23 (FGF-23), parathyroid hormone (PTH), and 1,25-dihydroxyvitamin D3
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(Calcitriol or 1,25(OH)2D) results in a negative feedback loop which regulates P
homeostasis.

Figure 2

PTH, 1,25(OH)2D and FGF23 reciprocally regulate their own
synthesis and control serum phosphate. In contrast, serum phosphate
or phosphate load can regulate production of PTH, 1,25(OH) 2D and
FGF23. Solid lines indicate stimulation of production or increase in
serum level. Broken lines mean inhibition of production or decrease
in serum level. PTH and 1,25(OH)2D are also regulated by serum
calcium (not shown in the figure).

Reprinted from reference(50)

Fibroblast growth factor-23 (FGF-23)
FGF-23, a hormone synthesized in the osteoclasts, regulates P balance by promoting P
excretion and inhibiting vitamin D circulation. A high dietary intake of P stimulates the
secretion of FGF-23, which in turn down regulates the expression of the NaPi cotransporters, resulting in phosphaturia. An increase in FGF-23 also limits intestinal P
absorption by reducing vitamin D production. FGF-23 inhibits renal 25-hydroxyvitamin
D 1- hydroxylase, the enzyme responsible for the conversion of 25(OH) D to 1,25(OH)2D
and also stimulates 24-hydroxlase production, a catabolic pathway for 1,25(OH)2D. As
nephron capacity diminishes, FGF-23 will rise in a physiological response to maintain
serum P levels. Not until the later stages of CKD are elevated serum P levels observed.
(53; 54)
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Parathyroid hormone (PTH)
Although the primary role of PTH is to regulate serum calcium levels, it has a secondary
effect in maintaining P homeostasis. By down regulating NaPi-2a and NaPi-2c in the
proximal renal tubule brush border, PTH reduces reabsorption of phosphate in the kidneys.
(55)

An elevated PTH also increases FGF-23 production, leading to diminished intestinal

phosphate absorption and increased renal phosphate excretion. Through a conflicting
effect, PTH indirectly enhances intestinal phosphate absorption by increasing the activity
of 1-α-hydroxylase enzymes, thus stimulating renal 1,25 D synthesis and also stimulates
release of calcium and phosphate from the bone. (56; 57)

1,25-dihydroxyvitamin D3 (Calcitriol or 1,25(OH)2D)
Vitamin D inhibits phosphate excretion directly repressing PTH and increases intestinal P
absorption by up-regulating NaPi-2b expression; however, unlike calcium, vitamin D is
not essential for the absorption of P.(58; 59)
To summarize, an elevation in PTH and FGF23 promote phosphaturia by down-regulating
sodium-P co-transporters in renal proximal tubule cells. FGF-23 also limits dietary P
absorption by reducing 1,25-dihydroxyvitamin D concentrations.

Hyperphosphatemia in Chronic Kidney Disease
Hyperphosphatemia, defined as high serum P levels greater than 1.46 mmol/L,
is common in late stage CKD and is associated with coronary artery calcification (CAC),
the development of secondary hyperparathyroidism (SHPT), left ventricular hypertrophy
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(LVH), mineral bone disorders (MBD), all-cause and cardiovascular mortality.(60)
Atherosclerotic and medial artery calcifications are two types of CAC.

Whereas

calcification of the intima, or innermost layer of the vasculature, is associated with
atherosclerosis resulting from inflammatory mediators and elevated lipids, medial artery
calcification is associated with stiffening of the blood vessels associated with age, diabetes,
and CKD.

Phosphate can stimulate the calcification of vascular smooth muscle cells

(VSMCs), which comprise the majority of medial cells.

This osteochondrogenic

transformation occurs independently of PTH and calcitriol levels.(61; 62) Phosphate has both
indirect and direct effects on PTH secretion and the development of secondary
hyperparathyroidism in CKD. High dietary P (via increased circulating concentrations of
FGF-23) lowers calcitriol levels, thus stimulating PTH. (61) Chronic hyperphosphatemia in
CKD leads to hyperplasia of the parathyroid glands, resulting in elevated PTH levels

(63)

This increase in PTH stimulates release of P from the bone, leading to CAC. Both dietary
phosphate and PTH increase FGF-23 levels. Consequences of prolonged exposure to FGF23 in CKD include increased prevalence LVH, resulting from direct inducement of
cardiomyocyte hypertrophy via the phospholipase C (PLC) γ/calcineurin/nuclear factor of
activated

T-cells

(NFAT)

pathway.

This

cardiovascular

complication

affects

approximately 75% of patients beginning RRT. (64)

Sudden death, arrhythmia, and unknown were the most common causes of cardiac death
reported in the USRDS and Hemodialysis (HEMO) study.

LVH, cardiac fibrosis, and

electrolyte anomalies may have been the underlying factor in these CVD deaths.

(21)

Numerous studies have found an association between elevated serum P and an increased
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risk in cardiovascular morbidity and mortality in ESRD patients, which may be attributed
to the presence of CAC and accelerated atherosclerosis. (65)

Phosphate levels are central to chronic kidney disease-mineral and bone disorder (CKDMBD), a syndrome that defines the mineral, hormonal, bone remodeling anomalies, and
vascular and soft tissue calcification that occur in CKD. Abnormalities in calcium, P, FGF
23, PTH, and vitamin D metabolism lead to CKD-MBD and are associated with increased
morbidity and mortality. (66)

Phosphate control in dialysis
Removal of phosphate during the dialysis procedure differs from urea or other small
molecules. Water molecules bind to P, converting what was originally a small molecule
into one of medium size, making passage through dialysis pores more difficult. Transfer
rate of phosphate from intra to extracellular compartments additionally limits removal
during dialysis. Slow shifts from the intracellular, or inaccessible space, to the extracellular
compartment and accessible plasma pose a barrier to phosphate removal. As a result,
serum P levels drop quickly during the first hour of dialysis, and then stabilize; therefore,
longer dialysis sessions result in greater P removal. With dietary P intakes of 0.8 to 2.0
grams per day, the average P removal of 800–1200 mg/session does not remove enough P.
Use of phosphate binders is commonplace as an adjunct therapy to both dietary restriction
and P removal from dialysis; however, these complementary measures of P control should
not downplay the importance of dietary P restriction. Within a healthy population, a high
dietary P intake, even in the absence of elevated serum P, is associated with increased
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mortality.(67) A drop in serum P levels as a result of reduced dietary P intake and P binders
use has been shown.(60; 68; 69) However, relying on measures of serum P to gauge dietary
control of this mineral has been criticized as unreliable due to inaccurate measurement
techniques, frequency and timing of serum samples, and tendency with daily fluctuations
in serum levels, potentially providing false assurance that P intake is controlled.
Alternative biomarkers, such as FGF-23 and PTH have been suggested as better measures
of cumulative P burden. (70; 71)

Metabolic Acidosis
Metabolic acidosis is a CKD induced complication as a result of reduced hydrogen ion
excretion, primarily from the metabolism of sulfur containing amino acids. Although
buffers, such as bicarbonate, are added to the dialysate to correct the acidosis, many
patients remain acidotic. Metabolic acidosis stimulates net pro catabolism, increases
oxidation of branched chain amino acids (BCAA), suppresses albumin synthesis,
negatively impacts bone metabolism, and impairs glucose tolerance.

(72)

Correction of

acidosis may reduce pro wasting and restore BCAA muscle pro concentration; however,
treatment of acidosis may only improve impaired pro synthesis in the absence of
inflammation. (73; 74)

Diets that produce large acid loads from the consumption of excess nucleic and amino acids
in meats coupled with inadequate intakes of organic bases from fruits and vegetables may
not only lead to low normal plasma bicarbonate concentrations, but also may impair
calcium and pro metabolism. (75)
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Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
CKD-MBD, a term originating from the Kidney Disease Improving Global Outcomes
(KDIGO) group, describes the complex of mineral and skeletal disorders and vascular and
soft tissue calcification resulting from abnormalities of calcium, P, PTH, or vitamin D
metabolism caused by CKD. Mineral bone disorders are among the non-traditional risk
factors which contribute to the high rate of cardiovascular morbidity and mortality
observed in CKD.
factors.

(76)

Efforts to control one factor can negatively impact remaining

For example, vitamin D supplements, often prescribed to HD patients, can

increase the risk of hyperphosphatemia through increased GIT absorption of phosphate as
well as stimulation of bone resorption. (77; 78; 79)

Dietary Phosphate
Challenges in menu planning and dietary adherence exist for the HD population as they are
instructed to restrict dietary P while increasing protein to 1.2 grams per kg body weight,
with an emphasis of at least 50% of protein coming from foods of high biological value
(animal based foods).(31) Instruction presented to patients with hyperphosphatemia in
limiting dietary P, usually provided as a list of high P foods to avoid, may have the
unintended consequence of a reduced protein intake. Currently, HD patients are counseled
to reduce intake of dietary P by limiting or restricting foods high in P, including meat,
poultry, fish, dairy, beans, lentils, and nuts. This educational practice may explain why
improved survival among HD patients with prescribed dietary P restriction has not been
found.(80) Additional dietary restrictions for sodium, potassium and fluid make meal

19
planning and dietary adherence burdensome. Dietary protein intake for most dialysis
patients reported at < 1.0 gram per kg/day is inadequate to preserve muscle. A diminished
pro intake as a result of limiting dietary P may lead to PEW. Both low dietary pro intakes,
elevated dietary P intakes and elevated ratios of dietary P/pro intakes have been associated
with increased mortality in MHD patients.(1; 81) Ideally, HD patients would benefit from a
diet which is both high in pro and low in bioavailable P. Using a ratio of milligrams of P
per gram of pro, or P/pro ratio, to identify foods which are both high in pro and low in P
has been suggested as a potential strategy in meal planning. Taking into account loss of P
through various cooking methods, P bioavailability, and pro to P ratios, D’Alessandro, et.
al has proposed a phosphorus pyramid tool (see Figure 3) as a guide to choosing foods
both high in protein and low in bioavailable P. Authors of the pyramid suggested an upper
limit of 12 mg/g to identify foods with a favorable phosphorus to protein ratio(82), a level
in agreement with The National Kidney Foundation Kidney Disease Outcomes Quality
Initiative (NKF KDOQI) guidelines of a recommended a daily P intake of 10 to 12 mg/g
of protein.(83) Animal proteins vary in their phosphorus and protein content. A whole egg
contains 6 g of protein and 86 mg of phosphorus, whereas the egg white contains 3.6 g
protein and only 5 mg of phosphorus, a P/pro ration of less than 2 mg/gram.(84)
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Figure 3
Phosphorus Pyramid

reprinted from reference(82)

About 40 to 60% of organic P, found in animal based foods and plants, is absorbed, whereas
the bioavailability of inorganic P, found in processed foods, is almost 100%. Given
humans do not express the enzyme phytase, which is required to hydrolyze phytic acid or
phytate, the storage form of P found in plants, the P content of plant pro may not reflect
actual absorption.(84) Yet, this diminished bioavailability of phosphorus from vegetarian
sources of protein is not considered in renal menu planning, nor reflected in nutrient data
bases.
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Phosphorus additives, used by the food industry as acidity regulators, preservatives,
thickeners, emulsifiers, flavor enhancers and stabilizers, may contribute as much as 1000
mg/d of phosphorus to the diet.(85; 86) A recent 2010 survey of almost 2400 processed
grocery items revealed that 44% contained added P.(87) Currently, the United States
Department of Agriculture (USDA) food composition data base lists total amount of P per
serving, but does not distinguish between inorganic and organic P content. Additionally,
the P content listed in nutrient databases does not always reflect the actual P content, and
has been shown to underestimate P by as much as two to three fold. (88) Both the USDA
and the Ministry of Health in Malaysia require that manufacturers label for the presence of
phosphates or polyphosphates on food labels; however, P amount is not a requirement for
the nutrient fact panel. Because the amount of P is not listed as a nutrient on food labels,
HD patients must be educated in identifying inorganic P additives, such as “monosodium
phosphate”, “phosphoric acid”, and “sodium hexametaphosphate”, on ingredients labels.
Despite food labeling laws, an independent analysis of food labels of enhanced
uncooked meat and poultry products found that manufacturers do not always
disclose additives ingredients, making it impossible to estimate phosphorus and
potassium content.(89) Fast foods, processed meats such as ham and sausage, processed
cheeses, canned fish, baked goods and cola type beverages, typically contain large amounts
of added phosphate.(90)
Additionally, various cooking methods have been evaluated to measure their effect on P
content. Boiling sliced meats in soft water or use of a pressure cooker has been shown to
reduce P content as much as fifty percent while preserving pro content.(91) Phosphorus

22
content of pasta, rice, fresh and frozen vegetables can be reduced from 7% up to 43% by
soaking and boiling methods.(92)

Phosphate Binders
In conjunction with limiting dietary P, both prescription and non-prescription phosphate
binders are taken with meals to reduce P absorption in the gastrointestinal tract. Binders
are generally classified as calcium based and non-calcium based, with the most commonly
prescribed binders reported as calcium-based agents despite known associations with
cardiovascular calcification.

Calcium based binders, such as calcium carbonate and

calcium acetate, are inexpensive, tolerated well, and can lower parathyroid levels, factors
most likely related to their continued widespread use. In patients with elevated serum
calcium levels, known CAC or low serum PTH levels, calcium based binders are
contraindicated. Two non-calcium based binders, sevelamer and lanthanum, are both
associated with increased gastrointestinal side effects and sevelamer binds with bile salts,
reducing lipid levels and potentially interfering with the absorption of fat soluble vitamins.
Among all chronic disease categories, the HD population has one of the highest pill
burdens. Results from a cross-sectional study of 233 prevalent US dialysis patients found
that from an average burden of eleven pills, 49% were phosphate binders with a 70%
patient adherence rate.(93; 94)

P absorption in the intestine is dependent upon the amount dietary P, bioavailability, use
of P binders, and presence of 1,25(OH)2 vitamin D. Additional barriers to controlling P
may be related to patient education. Erroneous beliefs that phosphate restriction is not
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necessary with binder use, poor adherence to binder use, unknown associations between
hyperphosphatemia and CAC, and confusion in which foods are high in P may all be
associated with hyperphosphatemia.(95)

The dialysis diet contradicts a healthy eating pattern.

Difficulty in planning and

implementing dietary restrictions often results in inadequate nutrient intakes. Whole
grains, pulses, nuts, fruits and vegetables are typically restricted in the renal diet due to
their higher content of potassium and P, yet intake of these foods are associated with
reduced CVD and overall mortality.(96; 97; 98)
Dietary P intake can be reduced without compromising pro consumption by choosing foods
with P/pro ratios less than 12 mg/g, avoiding foods with phosphate additives, and
employing cooking techniques which lower the P content.(82; 99)
Poor outcomes related to both hyperphosphatemia and PEW within the HD population
have been well documented; however, to our knowledge, there have been no published
studies examining intakes of P/pro ratios and PEW relationships in Malaysian HD patients.

CHAPTER III: Methodology

Study Design and Patient Recruitment
This cross sectional study was part of a baseline screening protocol for an interventional
Vitamin E tocotrienol clinical trial entitled PATCH (Palm Tocotrienols in Chronic
Hemodialysis) to evaluate treatment effects on lipoprotein panels and inflammatory
biomarkers. Patients were recruited from two dialysis non-governmental organization, or
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NGO, (National Kidney Foundation) clinics and two government hospitals in the Klang
Valley, Malaysia, between October 2015 through March 2016.
A sample of sixty MHD patients taken from four clinics (15 patients per clinic) were chosen
from a larger screening pool (40 patients per clinic) based on the completion of data
recorded.
Inclusion criteria for the study included patients aged 18-70 years, willing to provide
informed consent, receiving thrice weekly HD treatment for at least three months.
Exclusion criteria included poor adherence to prescribed medication and HD regimen and
impaired cognitive and functional abilities. This study (Nutritional Status and Lifestyle
Assessment among HD Patients in Malaysia) was approved by the Medical Research and
Ethics Committee, Ministry of Health, Malaysia (NMRR-15-865-25260) and Medical
Research Ethics Committee of National University of Malaysia (NN-039-2015).

Demographic and medication data collection
Demographic and prescription medication information obtained from the medical chart
was reviewed with the patient for accuracy.

Anthropometric and body composition measurements
Pre and post dialysis weights were taken using a SECA digital scale (Model 220, SECA,
Germany) and height was measured using a stadiometer to derive BMI (kg/m2). Triceps
skinfold thickness (TSF) measurement was taken on the non-fistula arm using a Harpenden
skinfold caliper (HSK-BI, British Indicators, West Sussex, UK). Mid-upper arm
circumference (MAC) was measured using a non-stretch Lufkin® metal measuring tape
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(Apex Tool Group, LLC, NC, USA). International Society for the Advancement of
Kinanthropometry (ISAK) techniques were employed in the measurements for MAC and
TSF(100). MAMC and MAMA measurements were derived using the formulas listed in
Table 3. Hand grip strength (HGS) was measured using a Jamar dynamometer (BK-7498;
Fred Sammons, Inc., Burr Ridge, IL) on the non-fistula hand prior to the patient’s dialysis
session. Three measurements were taken in the standing position, and the mean value was
used in all statistical analyses. All anthropometric measurements were performed by an
International Society for the Advancement of Kinanthropometry (ISAK) trained dietitian
to eliminate inter-observer variation.

Prior to the HD session, body composition

measurements were completed using a portable bio-impedance spectroscopy monitor
(Body Composition Monitor, Fresenius Medical Care, Bad Homburg, Germany). The
body composition monitor (BCM) used body weight, height, and measurements of whole
body intracellular water (ICW) and extracellular water (ECW) using bioimpedance
spectroscopy to determine lean tissue mass (LTM), adipose tissue mass (ATM) and
overhydration (OH).(101)

Biochemical analysis
Serum samples for routine renal biochemistry (serum albumin, potassium, P, hsCRP, and
lipid profiles) were analyzed using standard automated laboratory techniques by an
external laboratory (Roche/Hitachi 912 System, Roche Diagnostics, Tokyo, Japan).

3-day dietary recall collection and analysis

26
Per KDOQI guidelines, 3-day dietary recalls, including two non-dialysis and one dialysis
day, were collected by trained dietitians using household measures to estimate portion
sizes.(102) Nutrient analysis of the diet records were analyzed using the Nutritionist Pro
software (Nutritionist Pro™ 2.2.16, First DataBank Inc., 2004). Dietary energy intake
(DEI) and dietary pro intakes (DPI) were calculated based on the patient’s dry weight.

QOL (Quality of Life)

The Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney disease-specific
measure of health-related quality of life (HRQOL), was administered by a trained dietitian.
The survey contains questions related to generic chronic disease as well 24 kidney disease
specific questions. A scoring instrument was used to summarize the questions into four
scores: effects of kidney disease, burden of kidney disease, SF-12 physical composite, and
SF-12 mental composite [SF-12 refers to the generic core derived from the Medical
Outcomes Study Short Form 36 (MOS SF-36), which measures eight domains: physical
functioning, role limitations due to physical health, role limitations due to emotional
problems, energy/fatigue, emotional well-being, social functioning, pain and general
health]. Scores ranged from 0%, equivalent to maximum disability, to 100%, equivalent
to zero disability.(103)

PEW assessment
Patients satisfying PEW criteria per the ISRMN were identified, and PEW prevalence was
assessed. Serum chemistry, BMI, muscle mass, and dietary intake parameters used
included albumin < 3.8 mg/dL, BMI < 23 kg/m2, MAMC below the 10th percentile of the
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normal population from the NHANES I study, and a dietary energy intake of < 25 kcals/kg
body weight, respectively.(31; 104)

Statistical analysis
Variables are presented as mean ± SD, or frequency (percentages). The normal distribution
for continuous variables was assessed using Kolmogorov-Smirnov (K-S) test.
Comparisons were performed by the Student’s-t and Mann-Whitney tests for continuous
variables, with and without normal distribution, respectively. Comparisons of frequencies
were carried out by the Fisher test. Differences between groups were analyzed using oneway ANOVA and Kruskal-Wallis H Tests, with and without normal distribution,
respectively. Linear relationships for continuous variables were evaluated using Pearson’s
correlation. Categorical variables were evaluated for association using Pearson’s ChiSquare test. Statistical analyses were carried out using SPSS version 23 (IBM, Chicago,
IL, USA). Statistical significance was set at P < 0.05 for all evaluated parameters. A nonsignificant p value of 0.05 < p ≤ 0.10 was used for discussion purposes.
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CHAPTER IV: RESULTS

Patient Characteristics
Table 4 outlines the demographics of the sample (n=60) HD population. Almost half of
the patient population was Chinese, over one-third Malay, and over one-eighth Indian.
Males and females were equally distributed among the sample population. Over two-thirds
of the group had at least a secondary education and over two-thirds were unemployed.

Table 4 Demographic characteristics of the study population
Demographics (n=60)
Age (years)
Ethnicity (%)
Chinese
Malay
Indian
Others
Sex
Males (%)
Females (%)
Marital Status (%)
Married
Single
Education
None
Primary
Secondary
College/University
Employed
Yes
No

55.1 ± 13.3
29 (48.3%)
21 (35%)
9 (15%)
1 (1.7%)
32 (53.3%)
28 (46.7%)
48 (80%)
12 (20%)
4 (6.7%)
15 (25%)
28 (46.7%)
13 (21.7%)
17 (28.3%)
43 (71.7%)

Data are expressed as mean ± SD or percentage
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Anthropometric and body composition measurements were compared between genders as
outlined in Table 5. As anticipated, both mean and highest HGS measurements, lean tissue
mass, height, and MAC was found to be significantly higher for males when compared to
females.

Table 5 Anthropometric and Body Composition Measurements

Age (y)
Time on dialysis (mo)
Body weight (kg)
Stature (cm)
BMI (kg/m2)
MAC (cm)
TSF(mm)
MAMC (cm)
MAMA (cm2)
Lean Tissue mass (kg)
Fat Tissue Mass (kg)
HGS – mean (kg)
HGS – highest (kg)

ALL
(n=60)

Men
(n= 32)

Women
(n=28)

55.1 ± 13.3
90.9 ± 70.8
62.9 ± 18.8
156.7 ± 7.8
25.4 ± 6.3
30.1 ± 6.3
18.7 ± 8.9
24.2 ± 5.1
48.0 ± 22.1
32.8 ± 10.9
21.7 ± 10.4
18.6 ± 6.1
19.8 ± 6.3

55.4 ± 14.5
98.1 ± 73.9
64.8 ± 23.3
160.8 ± 6.6
24.8 ± 7.3
29.0 ± 6.7
15.0 ± 6.1
24.3 ± 5.4
48.5 ± 26.2
38.1 ± 11.9
19.4 ± 11.5
21.7 ± 6.4
22.9 ± 6.7

54.8 ±12.0
82.9 ± 67.5
60.7 ± 11.7
152.0 ± 6.2
26.1 ± 5.0
31.3 ± 5.7
23.0 ± 9.7
24.1 ± 4.8
47.5 ± 16.7
26.8 ± 5.0
24.4 ± 8.4
15.1 ± 3.2
16.4 ± 3.3

P for
comparison
between
genders
0.609
0.366
0.534
<0.0005
0.103
0.017
0.001
0.801
0.722
<0.0005
0.002
<0.0005
<0.0005

BMI: body mass index; MAC: mid-arm circumference; TSF: triceps skin fold; MAMC: mid-arm muscle
circumference; MAMA: mid-arm muscle area; HGS: hand grip strength
Data are expressed as mean ± SD; Mann-Whitney U Test
Statistically significant variables are given in bold

Average intakes from the three-day diet recall for HD nutrients of concern were evaluated
against KDOQI guidelines and between genders as demonstrated on Table 6. As expected,
overall intake for males was higher than that for females. Intakes for P, sodium, and fluid
fell within KDOQI guidelines; however, neither males nor females met calorie goals of 30
to 35 kcals per kg or pro goals of 1.2 grams per kg body weight.(31)
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Table 6 Nutrient Intake Analysis of 3 Day Diet Recall

Energy
(kcals)
Pro (g)

1445 ± 393

Nutrient Intake Analysis
Men
Women
P for
(n= 32)
(n=28)
comparison
between
genders
1512 ± 454 1370 ± 299 0.163

54 ± 18

57 ± 19

50 ± 18

0.197

Potassium
(mg)
Sodium
(mg)
P (mg)

990 ± 403

1049 ±449

923 ± 340

0.229

2511 ±
1583
618 ± 214

2419 ±
1226
667 ± 227

2060 ± 910

0.219

563 ± 189

0.062

Fluid (ml)

1002 ± 325

1064 ± 331

932 ± 309

0.118

DEI
(kcals/kg
dry wt.)
DPI (gms
pro/kg dry
wt)

24.0 ± 7.7

24.4 ± 7.8

23.6 ± 7.8

0.709

0.90 ± 0.38

0.9 ± 0.35

0.9 ± 0.41

0.704

All

NKF
KDOQI
guidelines(31)
Based on
BW
Based on
BW
Based on
serum levels
<2400 mg
10-17
mg/kg/day
(~630-1071)
750-1500
cc/day
30-35
kcals/kg
1.2 gms/kg
aBWef^

^edema-free adjusted body weight
Data are expressed as mean ± SD as analyzed by Student’s t-test

P/pro Ratio
Average ratio of P/pro intake for the entire sample population was 11.9 mg/g ± 3.2. P/pro
ratio was further stratified into favorable (< 12 mg/g) and unfavorable (> 12 mg/g) groups
of P/Phos intakes (see Table 7)(82). Average ratios of P/pro intake of the favorable and
unfavorable group were 9.8 ± 1.6 and 15 ± 2.3, respectively. Differences in various
biochemical, anthropometric and dietary intakes between the favorable and unfavorable
groups were analyzed. P/pro ratio, serum potassium, dietary P, dietary pro, and KDQOL
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SF-12 physical composite scores were significantly improved with favorable P/pro intakes
when compared to unfavorable intakes. Favorable P/pro intakes were also associated with
higher intakes of protein per kg of body weight, lower total serum cholesterol and reduced
inflammation, as measured by hsCRP.
Table 7 Relationship of P/pro ratio (<12 mg/gram and >12 mg/gram) and
biochemical, anthropometric and dietary intake

P/pro ratio
(mg/gram)
Serum Phos
(mg/dL)
Serum K
(mEq/L)
Serum alb
(g/dL)
Total
cholesterol
(mg/dL)
Lean tissue
mass
Fat tissue mass
ECFv/TBW
BMI (kg/m2)
hsCRP (mg/L)
Dietary Phos
(mg)
Dietary Pro (g)
DPI (grams/kg)
DEI (kcals/kg)
KDQOL SF-12
Physical
Composite
MAMC (cm)
MAMA (cm2)
Mean HGS (kg)

P/pro ratio <12
mg/gram
(n=35)
9.8 ± 1.6

P/pro ratio
> 12 mg/gram
(n=25)
15 ± 2.3

P value

5.36 ± 1.3

5.39 ± 1.7

0.921

2.81 ± 1.0
(n=10)
3.96 ± 0.36

3.5 ± 0.39
(n=12)
3.84 ± 0.34

0.019

162 ± 32

179 ± 48

0.100

33.5 ± 11.5

32.3 ± 10.2

0.762

22.0 ± 11.6
1.97 ± 0.45
25.8 ± 7.2
5.00 ± 4.9
559 ± 190

21.3 ± 8.7
1.78 ± 0.34
25.9 ± 4.9
7.6 ± 7.5
702 ± 223

0.781
0.111
0.601
0.105
0.013

59 ±19
0.97 ± 0.4
24.1 ± 7.6
46 ± 9

47 ± 15
0.80 ± 0.3
24.0 ± 8.3
40 ± 8

0.033
0.086
0.956
0.010

25.1 ± 5.5
51.8 ± 26.3
19.2 ± 6.5

23.0 ± 4.2
42.6 ± 13.2
17.7 ± 5.5

0.112
0.114
0.361

<0.0005

0.204
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Phos: P; K: Potassium; alb: albumin; ECF: extra cellular fluid: TBW: total body water; hsCRP: high
sensitivity C-reactive pro; DPI: dietary pro intake; DEI: dietary energy intake; KDQOL: Kidney Disease
Quality of Life
Data are presented as mean ± SD; statistical significance measured by Kruskal-Wallis H Test
Statistically significant variables are given in bold

As illustrated in Figure 4, favorable P/pro intakes were associated with a lower serum
potassium (K), hsCRP, improved KDQOL SF-12 physical composite scores, higher HGS,
and MAMC. The favorable ratio is influenced equally by P and pro intakes.

Figure 4 Relationship of P/pro Ratios and various clinical indicators
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The mean hsCRP in the favorable and unfavorable P/pro groups were 5.0 ± 4.9 and 7.6 ±
7.5 (p = 0.105), respectively, as depicted in Figure 5. Although not significant, these
differences reflect a trend towards increased inflammation with higher P/pro ratio intakes.

Figure 5 Relationship of P/Pro Ratio
(< 12 mg/gram and > 12 mg/gram) and hsCRP
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Within each ethnic group, 76% of Chinese and 57% of Malay patients had P/pro intakes in
the favorable range (< 12 mg/g) in comparison to 11% of Indian patients, as illustrated in
Figure 6.
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Figure 6 Comparison of P/pro Ratios and Ethnicity
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In comparing diet and exercise habits between favorable and unfavorable P/pro intakes,
those patients consuming unfavorable ratios were 44% less likely to exercise in comparison
to those consuming favorable ratios, who were 65% more likely to exercise. Both groups
reported similar dietary habits regarding food preparation, food consumption outside of the
home, and dietary counseling (see Figure 7).
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Figure 7
Comparison of P/pro ratios and diet/exercise habits
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Phosphate Binders
Among the phosphate binders prescribed to this Malaysian population, 91.7% take calcium
carbonate, with less than 12% using non-calcium based binders as depicted in Figure 8.

Figure 8 Prescribed Phosphate binders
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Measures of Muscle Mass
As illustrated in Table 8, in comparing various measures of muscle mass, MAMC and
MAMA were significantly correlated with measurements of lean tissue mass, fat tissue
mass and BMI. Mean HGS was significantly correlated with MAMA, and lean tissue mass.

Table 8 Matrix of Pearson’s correlation coefficients among HGS, anthropometric,
and body composition variables

Variable
BMI (kg/m2)
MAMC (cm)
MAMA (cm2)
Lean tissue
mass
Fat tissue
mass
Mean HGS
(kg)
P < 0.01**
P < 0.05*

BMI

MAMC

MAMA

0.752**
0.815**
0.448**

0.962**
0.447**

0.517**

0.878**

0.637**

0.710**

0.123

0.167

0.238

0.255*

0.645**

n= 60 (32 men and 28 women)

Lean
Tissue
mass

Fat
tissue
mass

0.014
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Anthropometric, body composition and biochemical measurements of those HD patients
who answered “yes” when asked if they engaged in any form of exercise were compared
to those patents who reported no physical activity (see Table 9). Those who exercised
had a significantly lower BMI (22.3 ± 3.8) than non-exercisers (26.7 ± 6.7). Exercisers
also had a significantly lower fat tissue mass (16.8 ± 5.6) and MAMC (21.7 ± 5.3) than
non-exercisers (23.8 ±11.3, 25.3 ± 4.7, respectively). Although not significant, those who
reported exercising showed trends towards higher serum HDL, serum albumin and lower
hsCRP levels.

Table 9 Anthropometric, Body Composition and Biochemical Measurements of
exercisers vs non-exercisers
Do you
exercise?
BMI (kg/m2)
Mean HGS (kg)
Serum HDL
(mg/dL)
Serum hsCRP
(mg/L)
Serum alb
(mg/dL)
Lean tissue
mass
Fat tissue mass
MAMC (cm)

Yes (n=18)

No (n= 42)

P value

22.3 ± 3.8
19 ± 6.4
43 ± 14

26.7 ± 6.7
18 ± 6.1
41 ± 11

0.012
0.741
0.528

4.6 ± 5.4

6.7 ± 6.4

0.216

4.0 ± 2.4

3.9 ± 3.9

0.219

32.5 ± 8.9

32.9 ± 11.7

0.880

16.8 ± 5.6
21.7 ± 5.3

23.8 ±11.3
25.3 ± 4.7

0.017
0.011

Data are expressed as mean ± SD as analyzed by one-way ANOVA
Statistically significant variables are given in bold
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PEW
The following diagnostic criteria was used to identify patients with a PEW diagnosis:





Alb < 3.8 mg/dL
BMI < 23 (kg/m2)
MAMC < 10% (percentile of the normal population from the NHANES I
study)(31)
DEI < 25 kcals/kg

As depicted in Figure 9, among those patients with three diagnostic criteria for PEW a
higher percentage (20%) consumed unfavorable P/pro intakes compared to 11%
consuming favorable intakes. Conversely, 20% of those patients with no PEW parameters
were in the favorable P/pro group in contrast to 8% in the unfavorable group. While not
significant, a larger sample size may reveal greater differences in P/pro intakes among the
PEW and non- PEW groups.

Figure 9 Relationship of PEW and P/pro Ratio

11%

Three parameters

20%

23%
20%

Two parameters

PEW
46%

One parameters

No parameters

52%

20%
8%

Phos/Pro < 12 mg/g

Pearson’s Chi-Square; p = 0.515

Phos/Pro > 12 mg/g
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Table 10 outlines PEW prevalence for both the entire population and within each ethnicity.
Overall PEW prevalence in this population was calculated at 15%. In comparison to
Chinese and Indian ethnicities, Malay patients exhibited the fewest clinical indicators of
PEW, while 22% of Indian patients and 17% of Chinese patients had three diagnostic PEW
criteria in comparison to 9% of Malay patients.
Table 10
Prevalence of PEW
Overall PEW Prevalence:
No diagnostic PEW criteria

15%

One diagnostic PEW criteria

48%

Two diagnostic PEW criteria

22%

Three diagnostic PEW criteria

15%

PEW prevalence within Ethnicities
Number of PEW parameters (% within ethnicity)
Ethnicity
None
One
Two
Three
29%
29%
33%
9%
Malay
10%
59%
14%
17%
Chinese
0%
67%
11%
22%
Indian
0%
0%
100%
0%
Others
Fisher’s Exact Test

P value
0.110
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CHAPTER V: DISCUSSION

P/pro ratio
Patients consuming favorable P/pro ratios had lower serum K, lower dietary P intakes,
higher dietary pro intakes, improved KDQOL physical composite scores, reduced levels of
hsCRP, higher DPI, and improved serum total cholesterol. This group also showed trends
towards improved measures of muscle mass and muscle strength. Noori, et. al, analyzed
P/pro intakes using food frequency questionnaires (FFQs) and found that both higher
dietary P intake and higher dietary P/pro ratios were each associated with increased death
risk in MHD patients; however, associations between P/pro ratio on biochemical and
anthropometric parameters were not addressed.(1)

A greater proportion of Chinese patients consumed favorable P/pro ratios, followed by
Malay patients, whereas Indian patient’s intake was of a predominantly unfavorable P/pro
pattern. Favorable P/pro intakes appear to be influenced more by traditional dietary intake
patterns rather than adherence to renal nutrition guidelines. Further exploration into the
types of foods chosen, methods of preparation, and meal and snack patterns may reveal the
underlying cause for this favorable intake of P/pro.

Measurements of muscle mass
One of the four main categories recognized in the diagnosis of PEW is muscle mass, as
measured by MAMA or creatinine appearance per ISRNM guidelines. Although reduction
in muscle mass is the most valid criterion for PEW diagnosis(11), the best method for taking
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this measurement has been debated.(105) Accurate assessment of MAMC and MAMA
requires training in anthropometry, yet it has been found that renal dietitians either lack the
skills to execute these measurements or fail to take body composition measurements.(106;
107)

In this study, results from both the BIA for lean and fat tissue masses and HGS, a

surrogate marker of muscle strength, were positively correlated with MAMA, with BIA
providing the strongest correlation. Similarly, Isoyama, et. al. found positive associations
between HGS and muscle mass in a study of MHD patients with a mean age of 53.(32) The
mean HGS in kg for both men and women was 21.7 and 15.1, respectively. Normative
HGS for a 55-year-old right-handed male is 45.9 and 26.0 for a female,(108) approximately
twice the strength than that found in this HD population. Currently, no standardized HGS
tables for the HD population exists. Given the ease and minimal training required to
complete BIA analysis and HGS test, consideration for use of these testing methods for the
HD population has been proposed as a complementary measurement to MAC and TSF for
determination of muscle mass.(35; 109)

In relation to the effects of exercise on body composition, the group of patients who
reported exercising had lower fat mass and BMI, and slightly higher HDL, serum albumin
and hsCRP; however, exercise did not improve their measures of muscle mass (lean tissue
mass and HGS). Our findings contrast reports that exercise, particularly resistance training,
improves muscle mass in HD patients; however, most published studies examining the
anabolic effect of exercise on muscle mass involve a younger HD population.(110; 111) Given
the median age of our study group was 55 years, sarcopenia related muscle wasting may
have offset the anabolic benefits derived from exercise.
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PEW
Fouque, et, al. reported that 18–75% of ESRD patients exhibit evidence of PEW;(11) we
found a similar PEW prevalence of 15%, with 22% of the patient population presenting
two PEW criteria and 48% with at least one diagnostic criteria.

No difference was found in the overall caloric intake between the favorable and
unfavorable P/pro groups. Both groups had an average consumption of less than 25 kcals
per kg. Per the IRSM guidelines for diagnosing PEW, an unintentional low dietary energy
intake of < 25 kcal/kg/day is one of the criteria in diagnosing PEW. Lower DEI and DPI
found in this Malaysian population produced slightly higher DEI for both genders and
lower DPI for men than that found in the HEMO study (DEI and DPI for men and women
in the HEMO study: 23.8 ± 8.4 and 21.7 ± 8.1, 0.97 ± 3.6 and 0.90 ± 3.4, respectively)(40)
In this study, an analysis was also completed using DPI in lieu of DEI in identifying PEW
patients; however, results did not produce significant differences.

Limitations of the Study

This study has several limitations. Estimation of total P intake was used in this analysis
since current nutrient databases do not distinguish between sources of inorganic and
organic P. The sample size was small, and a larger size may have been necessary to
produce statistically significant results between favorable P/pro intakes and PEW
parameters. Given patients typically underreport foods eaten, the values derived from
dietary recalls may have underestimated nutrient intakes, impacting identification of
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patients with PEW indices. Only one biomarker of inflammation (hsCRP) was measured;
additional inflammatory markers, such as ferritin, interleukin 6 (Il-6) and tumor necrosis
factor alpha (TNF-α) may have revealed stronger associations between P/pro ratio and
PEW parameters or have provided a biomarker in patients identified in exhibiting PEW
characteristics.

Conclusions and Recommendations
A mixed diet contains approximately 12–14 mg of P per gram of pro. Based on an upper
limit of 12 mg/g P/pro used to distinguish foods with a favorable ratio, a P pyramid has
been proposed by D’Alessandro, et. al. as a tool in dietary P management for CKD
patients.(82) By analyzing differences between favorable (< 12 mg/g P/pro) and unfavorable
(> 12 mg/g P/pro) intakes within this Malaysian HD study group in relation to various
biochemical and body composition parameters, it was found that favorable P/pro intakes
are inversely associated with PEW parameters of muscle mass and DPI. Both Chinese
ethnicity and exercise habits appear to drive favorable P/pro intakes. A secondary outcome
from this study includes findings that, when compared to measurements of MAMA, both
BIA analysis and HGS are both valuable markers for lean body mass. A larger data set of
HGS for the HD population would provide a valuable standard reference for the
identification of reduced muscle mass, which may be considered when diagnosing PEW.

Recommendation for future studies include data collection from a different ethnic group,
such as an African American population from the United States, to analyze differences in
both clinical care, PEW parameters, P/pro ratio, and the ethnic influences on food intake
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patterns. Additionally, a larger data set of HGS for the HD population would contribute to
standardized tables for the identification of reduced muscle mass, which may be considered
when diagnosing PEW.

In the Malaysian clinics, there was no restriction on eating during the HD session, a practice
which may allow for improved nutritional status.

In contrast, US clinics follow stricter

guidelines in allowing patients to eat while on HD.(112) Patient education practices differ
between countries as well.

The patient load per dietitian in the Malaysian non-

governmental organization (NGO) clinics was approximately 1 to 500, as opposed to the
median average in the United States of 1 to 150.(43) Examining the differences between
counseling approaches, education provided, patient behaviors, PEW parameters, and P/pro
ratio remains largely unexplored.
Educating HD patients about P containing food additives has been shown to reduced serum
P levels.(113) Examination of several written renal diet educational materials from both the
Academy of Nutrition and Dietetics’ Nutrition Care Manual and the National Institute of
Health’s National Kidney Disease Education Program (NKDEP) reveal that phosphorus
additives are addressed; however, information on the bioavailability of legumes, nuts,
seeds, and chocolate is not included, as these foods are listed only as high in P.
Additionally, neither the aforementioned materials, nor the phosphorus food pyramid
provides information on yeast leavened breads as a lower P choice over quick breads
leavened with baking powder. Gaps in nutrition education provided to HD patients related
to P/pro ratio and P bioavailability, coupled with a potentially over restrictive diet and high
pill burden that may lead to poor diet/binder adherence, diminished intakes of protein and
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lower intakes of antioxidant rich foods – factors implicated in hyperphosphatemia, PEW,
and increased all cause and cardiovascular mortality -- warrant further exploration with a
larger sample size. Should this larger sample demonstrate that favorable P/pro intakes are
associated with improved parameters of PEW, education with emphasis in choosing foods
based on the ratio of P/pro, rather than limiting foods based on P content alone, may be
warranted.
Furthermore, identification and validation of prognostic nutritionally related biomarkers
such as FGF-23, Fetuin A, and interleukin 6 (IL-6), remains an area of research that
requires full scale testing.(114) Additionally, potential use of an “omics” approach is
emerging as a promising method to identify new biomarkers in the pathogenesis of PEW
and phosphate control.(115)
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Both higher dietary phosphorus intake and a greater dietary phosphorus to protein ratio are
associated with increased death risk in hemodialysis (HD) patients even after adjustments
for serum phosphorus, type of phosphate binder used, and dietary protein, energy, and
potassium intake. Furthermore, dietary phosphorus restriction to control serum phosphorus
is often associated with a reduction in protein intake, which is associated with muscle
wasting and poor survival. One highly prevalent complication of end stage renal disease
is protein energy wasting (PEW), a state of decreased body protein and fat mass, which is
strongly associated with increased morbidity and mortality in the HD population.

In a cross sectional study of 60 Malaysian HD patients, the extent to which diet composition
associated with PEW parameters (serum chemistry, body mass, muscle mass, and dietary
intakes), was analyzed.

It was found that favorable phosphorus to protein (P/pro) intake was inversely associated
with PEW parameters of muscle mass and dietary protein intake. Both Chinese ethnicity
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and exercise habits appear to drive favorable P/pro intakes. A secondary outcome from
this study included findings that, when compared to measurements of mid-arm muscle area,
both bio impedance analysis and hand grip strength were both valuable markers for lean
body mass.

